Treatment of hyperprolactinemia: A single-institute experience.

Abstract

BACKGROUND:

Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Among known dopamine agonists, cabergoline is the drug of choice due to its enhanced tolerability compared with bromocriptine. This study aimed to evaluate cabergoline's effectiveness, along with transsphenoidal surgery, in the treatment of hyperprolactinemia.

METHODS:

We retrieved all patients with a diagnosis of prolactinoma who were treated in our hospital during 2000-2018. A total of 208 patients were enrolled in the analysis after applying exclusion criteria. Patients were divided into four groups according to the treatments received. The demographic data, dosage and duration of cabergoline, and serum prolactin levels at different time points were collected for analysis.

RESULTS:

Normalization was achieved in 59 patients (83.10%) within a short median duration of 2.80 months among those treated with cabergoline only. Although cabergoline alone was effective and well-tolerated, our data showed that long-term remission rates were more favorable when surgery was involved. The long-term remission rate of all patients enrolled was 53.8% (112 patients among 208 patients). The long-term remission rates for the different treatment groups were 17.8% (8 of 45 patients) in Group 1 (Operation→Drug), 83.3% (5 of 6 patients) in Group 2 (Drug→Operation), 79.0% (68 of 86 patients) in Group 3 (Operation only), and 43.7% (31 of 71 patients) in Group 4 (Drug only).

CONCLUSION:

Cabergoline has been demonstrated to be effective and should be considered as a first-line treatment for hyperprolactinemia. In our study, transsphenoidal surgery was also demonstrated to achieve good results compared with medical treatment. Surgical intervention may resurface as an alternative first-line treatment. When used in combination with cabergoline, surgery offers a higher disease remission rate than either drug or operation alone.

• Authors: Tse-Yu Chen, Chung-Hsin Lee, Meng-Yin Yang, Chiung-Chyi Shen, Yin-Ping Yang, Yueh Chien, Yu-Fen Huang, Chih-Ming Lai, Wen-Yu Cheng
• Journal: Journal of the Chinese Medical Association : JCMA (J Chin Med Assoc) Vol. 84 Issue 11 Pg. 1019-1022 (11 01 2021) ISSN: 1728-7731 [Electronic] Netherlands
• PMID: 34261980 (Publication Type: Journal Article)
• Copyright: Copyright © 2021, the Chinese Medical Association.

Chemical References

• Dopamine Agonists
• Cabergoline

Topics

• Adult
• Cabergoline (therapeutic use)
• Dopamine Agonists (therapeutic use)
• Female
• Humans
• Hyperprolactinemia (drug therapy)
• Male
• Middle Aged